TG Therapeutics, Inc. (TGTX)
55.37
+2.03
(+3.81%)
USD |
NASDAQ |
Oct 09, 16:00
55.00
-0.37
(-0.67%)
After-Hours: 20:00
TG Therapeutics Free Cash Flow (Quarterly) : 38.97M for June 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 38.97M |
| March 31, 2026 | -17.94M |
| December 31, 2025 | 19.59M |
| September 30, 2025 | -23.23M |
| June 30, 2025 | 7.394M |
| March 31, 2025 | -28.74M |
| December 31, 2024 | -25.66M |
| September 30, 2024 | -12.23M |
| June 30, 2024 | 5.536M |
| March 31, 2024 | -8.207M |
| December 31, 2023 | -13.21M |
| September 30, 2023 | 83.70M |
| June 30, 2023 | -42.00M |
| March 31, 2023 | -59.90M |
| December 31, 2022 | -23.87M |
| September 30, 2022 | -34.50M |
| June 30, 2022 | -49.12M |
| March 31, 2022 | -68.70M |
| December 31, 2021 | -86.99M |
| September 30, 2021 | -67.28M |
| June 30, 2021 | -60.34M |
| March 31, 2021 | -81.42M |
| December 31, 2020 | -52.18M |
| September 30, 2020 | -56.62M |
| June 30, 2020 | -43.88M |
| Date | Value |
|---|---|
| March 31, 2020 | -62.18M |
| December 31, 2019 | -30.43M |
| September 30, 2019 | -33.27M |
| June 30, 2019 | -35.88M |
| March 31, 2019 | -33.36M |
| December 31, 2018 | -33.70M |
| September 30, 2018 | -33.04M |
| June 30, 2018 | -34.22M |
| March 31, 2018 | -28.07M |
| December 31, 2017 | -21.85M |
| September 30, 2017 | -22.78M |
| June 30, 2017 | -26.83M |
| March 31, 2017 | -22.30M |
| December 31, 2016 | -17.04M |
| September 30, 2016 | -15.05M |
| June 30, 2016 | -12.88M |
| March 31, 2016 | -16.95M |
| December 31, 2015 | -12.88M |
| September 30, 2015 | -10.70M |
| June 30, 2015 | -12.26M |
| March 31, 2015 | -8.889M |
| December 31, 2014 | -15.12M |
| September 30, 2014 | -8.052M |
| June 30, 2014 | -3.573M |
| March 31, 2014 | -8.332M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| Krystal Biotech, Inc. | 71.22M |
| Vertex Pharmaceuticals, Inc. | 1.013B |
| SELLAS Life Sciences Group, Inc. | -7.588M |
| Travere Therapeutics, Inc. | 37.00M |
| Alnylam Pharmaceuticals, Inc. | 292.04M |